SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.720
-0.230 (-5.82%)
Nov 7, 2024, 11:27 AM EST - Market open
SAB Biotherapeutics Employees
SAB Biotherapeutics had 57 employees as of December 31, 2023. The number of employees increased by 1 or 1.79% compared to the previous year.
Employees
57
Change (1Y)
1
Growth (1Y)
1.79%
Revenue / Employee
$48,773
Profits / Employee
-$707,373
Market Cap
34.33M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 57 | 1 | 1.79% |
Dec 31, 2022 | 56 | -83 | -59.71% |
Dec 31, 2021 | 139 | 53 | 61.63% |
Dec 31, 2020 | 86 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Neuronetics | 203 |
ProPhase Labs | 113 |
Adagio Medical Holdings | 85 |
NextCure | 82 |
BioLineRx | 79 |
Curis | 49 |
Lumos Pharma | 33 |
Lantern Pharma | 21 |
SABS News
- 18 hours ago - SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire
- 7 weeks ago - SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewsWire
- 3 months ago - SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewsWire
- 3 months ago - SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewsWire
- 3 months ago - SAB BIO Appoints Lucy To as Chief Financial Officer - GlobeNewsWire
- 5 months ago - SAb Biotherapeutics Rebrands as SAB BIO - GlobeNewsWire
- 5 months ago - SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions - GlobeNewsWire